Dr. Jonathan Mizrahi and Dr. Shubham Pant explore emerging molecular targets in pancreatic cancer, starting with KRAS G12C and expanding to broader KRAS-directed strategies that may finally challenge the long-held “undruggable” label. While actionable mutations remain uncommon, they review current tumor-agnostic approvals, the limited role of immunotherapy outside MSI-high disease, and the ongoing search for effective biomarkers such as CLDN18.2. Vaccine-based approaches in earlier-stage disease are also discussed as a potential avenue for immune priming. Together, the discussion highlights cautious optimism that molecularly driven therapy may soon begin reshaping pancreatic cancer care.
Contributors:
Dr. Jonathan Mizrahi is a medical oncologist with Ochsner Health in New Orleans, Louisiana.
Dr. Shubham Pant is a professor with the Department of Gastrointestinal Medical Oncology and Investigational Cancer Therapeutics at the University of Texas MD Anderson Cancer Center in Houston, Texas.
